SUL-238 is under clinical development by Gen Ilac ve Saglik Urunleri and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SUL-238’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SUL-238 overview

SUL-238 is under development for the treatment of Alzheimer’s disease, chronic heart failure, chronic kidney disease, pulmonary arterial hypertension, sepsis-associated acute kidney injury and chronic obstructive pulmonary disease (COPD). It is a hydrochloric salt of the SUL-138 and is administered through oral route.

Gen Ilac ve Saglik Urunleri overview

Gen Ilac ve Saglik Urunleri engaged in supplying medical products utilized for the treatment of neurology, nephrology, endocrinology, hematology, oncology, pediatric diseases and disorders. The company is headquartered in Ankara City, Ankara, Turkey.

For a complete picture of SUL-238’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.